SAN FRANCISCO, Jan. 30, 2025 (GLOBE NEWSWIRE) -- Structure Therapeutics Inc. (NASDAQ: GPCR), a clinical-stage global biopharmaceutical company developing novel oral small molecule therapeutics for metabolic diseases, today announced that management will participate in multiple upcoming healthcare conferences being held in February and March. Guggenheim SMID Cap Biotech Conference Format:Fireside chat and 1x1 meetings Date/time:Wednesday, February 5 at 10:30 a.m. ET Location:New York, NY Webcast link:https: ...

Preclinical studies with ACCG-2671 demonstrate potent target engagement, robust weight loss, favorable safety profile and PK properties supportive of once-daily dosing in humans ACCG-2671 is the most advanced oral small molecule amylin-based drug candidate, with Phase 1 study initiation expected by year end 2025 Company to host conference call today at 4:30 p.m. Eastern Time SAN FRANCISCO, Dec. 17, 2024 (GLOBE NEWSWIRE) -- Structure Therapeutics Inc. (NASDAQ:GPCR), a clinical-stage global biopharmaceutical ...

A couple of analysts initiated coverage on Septerna, Inc. SEPN, which debuted on NASDAQ last month.Cantor analyst Josh Schimmer initiated coverage at an Overweight rating with a price target of $50.The analyst says that SEPN’s advanced platform accelerates the discovery of novel GPCR-targeting therapeutics, addressing a significant unmet need.Leveraging CryoEM technology, SEPN reconstitutes GPCRs in lipid bilayers, enabling structural analysis of targets previously deemed “undruggable.” This unlocks potenti ...

SAN FRANCISCO, Nov. 15, 2024 (GLOBE NEWSWIRE) -- Structure Therapeutics Inc. (NASDAQ: GPCR), a clinical-stage global biopharmaceutical company developing novel oral small molecule therapeutics for metabolic and cardiopulmonary diseases, today announced that management will participate in a presentation and fireside chat, and host one-on-one meetings at the Jefferies London Healthcare Conference being held November 19-21, 2024, in London, UK. Jefferies London Healthcare Conference  Format:Presentation and fi ...

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2024 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For The Transition Period From To Commission file number: 001-41608 Structure Therapeutics Inc. (Exact name of registrant as specified in its charter) Cayman Islands 98-1480821 ( ...

Exhibit 99.1 Structure Therapeutics Reports Third Quarter 2024 Financial Results and Recent Highlights First patients dosed in Phase 2b ACCESS study of GSBR-1290 for obesity Oral small molecule amylin receptor agonist development candidate expected to be selected by the end of 2024 Strong financial position with cash, cash equivalent and short-term investments of $915.3 million expected to fund projected operations and key clinical milestones through at least 2027 Conference Call to discuss GSBR-1290 ACCESS ...

Tokyo, Japan and London and Cardiff, UK, 5 November 2024 – Nxera Pharma ("Nxera"; TSE 4565) – formerly known as Sosei Group or Sosei Heptares – and Antiverse, a techbio company designing antibodies for challenging targets, have today announced a multi-target partnership and licensing agreement to design antibodies for G-protein coupled receptors (GPCRs). The collaboration combines Antiverse's generative AI antibody design expertise, including its proprietary machine-learning-generated 'epitope-specific libr ...

Here are three stocks with buy rank and strong momentum characteristics for investors to consider today, October 23:Structure Therapeutics Inc. (GPCR) : This biopharmaceutical company has a Zacks Rank #1 and witnessed the Zacks Consensus Estimate for its current year earnings increasing 8.1% over the last 60 days.Structure Therapeutics' shares gained 8.7% over the last three months compared with the S&P 500’s advanced of 7.7%. The company possesses a Momentum Score of B.Rush Enterprises, Inc. (RUSHA) : This ...

Structure Therapeutics Inc. Sponsored ADR (GPCR) closed the last trading session at $40.50, gaining 17.7% over the past four weeks, but there could be plenty of upside left in the stock if short-term price targets set by Wall Street analysts are any guide. The mean price target of $87.40 indicates an 115.8% upside potential. The mean estimate comprises 10 short-term price targets with a standard deviation of $15.90. While the lowest estimate of $65 indicates a 60.5% increase from the current price level, th ...

SAN FRANCISCO, Aug. 26, 2024 (GLOBE NEWSWIRE) -- Structure Therapeutics Inc. (NASDAQ: GPCR), a clinical-stage global biopharmaceutical company developing novel oral small molecule therapeutics for metabolic and cardiopulmonary diseases, today announced management will participate at the following investor conferences in September: Morgan Stanley 22nd Annual Global Healthcare Conference Fireside chat: Thursday, September 5 at 10:00 a.m. EDT Cantor Fitzgerald Global Healthcare Conference 2024 Fireside chat: T ...